Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Squalene epoxidase (SE), also known as squalene monooxygenase, is a key flavin adenine dinucleotide (FAD)-dependent enzyme involved in the ergosterol biosynthetic pathway in fungi. It catalyzes the conversion of squalene to 2,3-oxidosqualene, a crucial step for producing ergosterol, which maintains membrane integrity and function. SE is a validated target for antifungal drugs, particularly allylamines like terbinafine, which inhibit the enzyme and disrupt ergosterol synthesis. Inhibition leads to accumulation of squalene and depletion of ergosterol, disrupting membrane function and causing fungicidal effects.
Noncompetitive inhibition via conformational change, preventing substrate (squalene) binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Squalene Epoxidase (Fungal) (SE).